🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

13 recruiting trials

for C3G

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN NCT06209736Phase 26 sites📍 Kaunas📍 Vilnius📍 Auckland Omeros Corporation · Tests: OMS906 study drug Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS NCT05795140Phase 39 sites📍 São Paulo📍 Rio de Janeiro📍 Beijing Novartis Pharmaceuticals · Tests: Iptcaopan 200 mg Chinese Adults With Kidney Disease NCT07522099Phase 29 sites📍 Shenzhen📍 Guiyang📍 Zhengzhou ADARx Pharmaceuticals, Inc. · Tests: ADX-038, Telitacicept Predictive Value of a Rectal Swab With Detection of Enterobacteria (ESBL-E), Carbapenemases, and High-level Cephalosporinase (HLC) on the Risk of Infections With C3G-resistant Enterobacteria NCT07345923n/a1 site📍 Strasbourg University Hospital, Strasbourg, France A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy NCT07483827Phase 117 sites📍 Vienna📍 Brussels📍 Prague eleva GmbH · Tests: CPV-104/Placebo, CPV-104 Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN NCT03955445Phase 353 sites📍 Aurora📍 Lawrenceville📍 Iowa City Novartis Pharmaceuticals · Tests: LNP023 Home Reported Outcomes in C3G Study NCT07029542n/a1 site📍 East Hanover Novartis Pharmaceuticals Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease NCT06989359Phase 238 sites📍 Doral📍 Miami📍 Pembroke Pines ADARx Pharmaceuticals, Inc. · Tests: ADX-038 Dose Level 2, ADX-038 Dose Level 1 A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain NCT07598448n/a2 sites📍 Córdoba📍 Madrid Novartis Pharmaceuticals A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy NCT07416162n/a3 sites📍 Jeollanam📍 Seoul📍 Seoul Novartis Pharmaceuticals A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G NCT06419205Phase 24 sites📍 Hollywood📍 Lawrenceville📍 Orangeburg Akebia Therapeutics · Tests: ADX-097 Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study NCT07746895Phase 4101 sites📍 Kingswood📍 Woolloongabba📍 Graz Swedish Orphan Biovitrum · Tests: Pegcetacoplan Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. NCT04817618Phase 387 sites📍 Aurora📍 Miami📍 Lawrenceville Novartis Pharmaceuticals · Tests: Placebo, iptacopan
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy